Royal Bank of Canada
TBPH

Royal Bank of Canada’s Theravance Biopharma TBPH Stock Holding History

Royal Bank of Canada’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-48,900
Closed -$919K – 6517
2016
Q1 		$919K Buy
+48,900
New +$800K ﹤0.01% 3135

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Royal Bank of Canada's TBPH Position: Q2 2026 in Review

Royal Bank of Canada increased its Theravance Biopharma (TBPH) stake by 134% in Q2 2026, buying an estimated $84.4K and bringing the position to 8,907 shares worth $151K. The position accounts for ﹤0.01% of the portfolio, ranked #5154.

Royal Bank of Canada first reported a position in TBPH in Q2 2014 and has held it in 49 quarters since. The position peaked at $5.55M in Q2 2025. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Royal Bank of Canada held 8,907 shares of Theravance Biopharma worth $151K as of Q2 2026.
  • Royal Bank of Canada bought 5,097 Theravance Biopharma shares in Q2 2026, an estimated $84.4K.
  • Theravance Biopharma made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #5154 holding.
  • Royal Bank of Canada first reported a position in Theravance Biopharma in Q2 2014 and has held it in 49 quarters since.
  • Royal Bank of Canada's Theravance Biopharma position peaked at $5.55M in Q2 2025.
  • 180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.